Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2013; 8(8): e70967.
Published online 2013 August 5. doi:  10.1371/journal.pone.0070967
PMCID: PMC3733803

Elderly Men Have Low Levels of Anti-Müllerian Hormone and Inhibin B, but with High Interpersonal Variation: A Cross-Sectional Study of the Sertoli Cell Hormones in 615 Community-Dwelling Men

Renato Pasquali, Editor


The Sertoli cells of the testes secrete anti-Müllerian hormone (Müllerian inhibiting Substance, AMH) and inhibin B (InhB). AMH triggers the degeneration of the uterine precursor in male embryos, whereas InhB is part of the gonadal-pituitary axis for the regulation of sperm production in adults. However, both hormones are also putative regulators of homeostasis, and age-related changes in these hormones may therefore be important to the health status of elderly men. The levels of AMH in elderly men are unknown, with limited information being available about age-related changes in InhB. We have therefore used ELISAs to measure Sertoli cell hormone levels in 3 cohorts of community-dwelling men in New Zealand. In total, 615 men were examined, 493 of which were aged 65 or older. Serum AMH and InhB levels inversely correlated with age in men older than 50 years (p<0.001) but not in the younger men. A minority of elderly men had undetectable levels of AMH and InhB. The variation in hormone levels between similarly aged men increased with the age of men. AMH and InhB partially correlated with each other as expected (r = 0.48, p<0.001). However, the ratio of the two Sertoli hormones varied significantly between men, with this variation increasing with age. Elderly men selected for the absence of cardiovascular disease had AMH levels similar to those of young men whereas their InhB levels did not differ from aged-matched controls. These data suggests that Sertoli cell number and function changes with age, but with the extent and nature of the changes varying between men.


The testes contain two distinct endocrine cells, the androgenic Leydig cells and the Sertoli cells, which produce AMH and InhB. In male embryos, AMH triggers the degeneration of the uterine precursor [1], but the testes continue to secrete AMH throughout development and into adulthood [2], [3]. The AMH in blood has been presumed to be non-functional. However, its pattern of secretion is regulated, with conservation between species, ranging from fish to man [4]. This suggests that AMH may have undetected functions in animals and humans, as non-functional gene output degrades across evolutionary time. Consistent with this, AMH has been implicated in generating the male bias in parts of the murine nervous system [5], [6], [7] and lungs [8].

Recent studies also implicate serum AMH in human non-gonadal development. The level of AMH varies greatly between boys of similar age, with the interpersonal differences remaining stable over years [3], [9]. An individual boy’s level of AMH inversely correlates with his rate of maturation [9]. Similarly, in boys with an autistic spectrum disorder, their levels of AMH correlate with the breadth of their symptoms [10]. Men have lower levels of circulating AMH than boys [3], but the levels of AMH in men are nevertheless sufficient to effect responsive cells in vitro [11]. This suggests that AMH may have functions in adults, with regulation of the cardiovascular system being one emerging possibility [12], [13].

InhB is part of the gonadal pituitary axis and contributes to the regulation of sperm production [14]. Like testosterone, the actions of InhB appear to extend beyond primary reproduction to homeostasis. For example, the inhibins regulate bone, with the onset of osteoporosis in women being linked to declining levels of Inhibins during the menopausal transition [15]. Boys also produce InhB, despite their gonadal-pituitary being largely quiescent during childhood and their testes lacking sperm [16]. The function(s) of InhB in boys is unknown, but potentially important, as the levels of InhB in autistic boys are strongly and positively correlated with the breadth of their symptoms [10].

The classical functions of both AMH and InhB are independent of each other. However, AMH and InhB cooperate to suppress testicular cancer in mice [17]. In other circumstances, their effects on downstream signaling will generally be antagonistic [18]. Thus, for some functions the relative levels of AMH and InhB may have biological significance.

As noted above, both Sertoli cell hormones have well characterized classical functions, but with little exploration of their wider functions. Consequently, much of the basic information relating to these hormones is absent, including their circulating profiles across the lifespan of men. Ovarian production of both AMH and InhB decline during the menopausal transition, and is absent after the menopause. Testosterone secretion declines with age in most men [19], but with an average effect that is much less profound than the loss of ovarian steroids. Sertoli cell number declines with age [20], [21], but the effect of this on AMH production in elderly men is unknown, with only minimal information being available about InhB levels in elderly men [22].

This paucity of basic information makes it difficult to determine whether changes in Sertoli cell hormones might contribute to the deterioration of elderly men, and/or whether sex differences in age-related diseases are partially due the loss of gonadal protein hormones. We have therefore examined the levels of AMH and InhB, and the ratio of these two hormones, to produce the first description of Sertoli cell function in elderly men. We report that, on average, both Sertoli cell hormones are lower in elderly men, with wide variation between the two hormones suggesting age-related changes in both the regulation and the number of Sertoli cells.

Materials and Methods


All study participants gave written informed consent. The study of the Otago elderly subset cohort, and Vascular cohort were both approved by the Lower South Regional Ethics Committee of New Zealand, whilst the LiLACS NZ cohort study was approved by the Northern X Regional Ethics Committee of New Zealand. The younger Otago men study was approved by the University of Otago Human Ethics Committee.

Study Populations

Serum samples were collected from 615 men aged from 19 to 93 years, with a focus on elderly men (n = 496). The participants were drawn from three distinct cohorts (Table 1). A non-fasting 5 mL venous blood sample was obtained in the antecubital vein between 7 am and 3 pm. The blood was clotted, and the serum aliquoted and stored at −80 C.

Table 1
Characteristics of participants in three cohorts.

The Otago cohort was a cross-sectional study of 99 community dwelling men aged 70 or older, with 119 younger men as a comparison. The men were predominantly Caucasian and resided in Dunedin, a small university city in New Zealand. The exclusion criteria for this cohort was limited to a history of testicular tumor, testicular trauma, orchidectomy, undescended testes, self-reported infertility, chemotherapy or abdominal or pelvic radiation therapy. None of the men were on anti-androgen medication or steroid medications. The elderly men were recruited from community groups and clubs, including men receiving outpatient rehabilitation for physical or mental health (mood disorders or cognitive decline). The younger men were recruited from various facilities including staff and students at the local university, medical and non-medical hospital staff, light and heavy industrial occupation, civil service, and office-based private sector employees.

The vascular cohort was a distinct Dunedin cohort comprised of 153 community dwelling men aged 54–93 years, with no history of cardiovascular disease. These men were recruited from advertisements and screened for peripheral arterial disease and carotid stenosis. Men with a carotid stenosis of greater than 50% and men with an ankle-brachial pressure index of less than 0.9 or greater than 1.3 were excluded from this cohort. Their sera were obtained from the Vascular Research Group Biobank, University of Otago.

Sera from 257 elderly men were analyzed from the LiLACS NZ Research Group (Life and Living in Advanced Age: A Cohort Study in New Zealand; Te Puawaitanga o Nga Tapuwae Kia Ora Tonu). This is an ongoing epidemiological study investigating factors that lead to successful aging in elderly New Zealanders [23]. A cohort of 937 community-dwelling men and women were recruited in the East Coast (Bay of Plenty and Rotorua) of the North Island, from the electoral roll registry, with methodology described elsewhere [24]. Inclusion criteria were primarily based on age and ethnicity: Māori aged between 80–90 years old, and non-Māori aged 85 years old were recruited, with a response rate from men of 65%. Study participants had varying health and physical performance status measured, with the 257 men examined being those that had consented for their sera to be used for collaborative research. None of the participants reported a history of orchidectomy.

Laboratory Analysis

Serum AMH levels were measured in duplicate, with 575 of the 615 samples being measured with the enzyme immunoassay AMH/MIS kit (Beckman Coulter, Fullerton, CA; A16507, analytical sensitivity 1 pmol/L, 0.14 ng/ml). The other 40 were analyzed MIS/AMH ELISA (Diagnostic System Laboratories, Webster, TX; DSL-10-14400, analytical sensitivity 0.04 pmol/L, 0.006 ng/ml), which became unavailable after Beckman Coulter acquired DSL. The two kits give similar results [25], which was confirmed in our laboratory by analyzing over 100 samples unrelated to the current study, with both ELISA kits. The intra and interassay coefficient of variation (CV) were 8.8% and 10.3%.

Serum InhB levels was measured in duplicate by immunoassay (Beckman Coulter; A81303, with analytical sensitivity of 2.6pg/mL). The intra and interassay coefficient of variation (CV) were 6.5% and 12.6%.


The levels of the two Sertoli cell hormones varied between individuals. If this variation is examined using a simple ratio of the hormones (AMH/InhB) then the resulting distribution will be non-symmetrical. Individuals with high AMH will be represented on a scale from 1 to infinity whereas those with high InhB will have values between 0 and 1. The ratio was therefore calculated using the ratio of the natural logs of the hormones (ln(AMH)-ln(InhB)) which produces a symmetrical distribution, without bias to either hormone. When this ratio is standardized using the mean levels of the hormones in the young men, then the distribution centers around zero. Any variation from a normal distribution indicates biological skewing, with the width of the bell curve being a measure of the variation in the population: as per the normal distribution of each individual hormone.

Statistical Analysis

The associations between AMH, InhB and age were tested by linear regression. The AMH and InhB levels in the Otago cohort were compared with the data from the other two cohorts using the nonparametric Wilcoxon-Mann-Whitney test. Skewness was calculated and its significance tested using the SKTEST. All calculations were performed in Stata/IC 12.1 (StataCorp LP, College Station, TX).


The levels of Sertoli cell hormones in a cross-section of community dwelling men (n = 205, Otago cohort) were examined, with the sole exclusion criteria being pharmacological or physical manipulation of the testes.

AMH in Community-dwelling Men

The levels of AMH were highly variable between men, with a distribution that was positively skewed in both the younger and older men (Fig. S1). All younger men had AMH levels that were greater than 6.5 pmol/L (0.91 ng/ml). There was no effect of age on the levels of AMH in younger men (r = −0.05, n = 95, <50 years), after which there was a change in the profile of AMH levels (Fig. 1A). In the older men, there was a significant and progressive decline in the geometric mean for AMH, with a simultaneous increase in variability between the men: AMH was undetectable in 5% of the elderly men, with 10% having high levels of AMH, above the 95% confidence interval of the younger men (Fig. 1B). Consequently, the coefficient of variation (%CV) increased with age.

Figure 1
A cross-sectional study of the AMH levels across the adult lifespan of males.

Inhibin B in Community-dwelling Men

The profile of InhB was similar to that of AMH. InhB was less variable between individuals than AMH (cf Fig. 1A, ,2A),2A), and was normally distributed in the younger men (Fig. S2). An age-related change in InhB was only observed in the elderly. As with AMH, this involved a diminishing geometric mean with age, with a concurrent increase in CV (Fig. 2B). 20% of the elderly men had levels of InhB below 51 pg/ml (2.5th centile of the younger men).

Figure 2
A cross-sectional study of the serum InhB levels across the adult lifespan of males.

Hormone Balance in Community-dwelling Men

The relative levels of AMH and InhB varied between individuals, in both the young and the elderly (Fig. 3A). However, the levels of the two hormones were not completely independent as a linear regression between them was r = 0.48, p<0.001 (Fig. 3B).

Figure 3
A cross-sectional study of the balance of Sertoli cell hormones across the lifespan of men.

The Otago cohort was then compared to two other cohorts of elderly men, to determine the generalizability of the observations. The first comparison was between the community-dwelling Dunedin men, described above, and a second Dunedin cohort (n = 153) that had been selected for the absence of cardiovascular disease (vascular cohort). The levels of AMH in the vascular cohort were higher than the age-matched portion of the Otago cohort (Fig. 4A, p<0.001) and were not different from the younger part of the Otago cohort (Fig. p = 0.35). In contrast, the Otago and the vascular cohorts had similar age-related decline in InhB values.

Figure 4
A comparison of Sertoli hormone levels between 3 New Zealand cohorts.

The elderly portion of the Otago cohort (n = 99) was then compared with the LiLACS NZ cohort (n = 257), which was collected from a more northern community, with a different socioeconomic and ethnic composition. The age-matched AMH and InhB levels were not different between the cohorts, although 3.5% of the LiLACS NZ cohort had atypically high levels of InhB, which could not be attributed to race (Fig. 4D).

When the three cohorts were combined, the elderly men displayed larger divergence in the ratio of AMH and InhB, in both the positive and negative directions. The vascular group had a prominent AMH bias (Fig. 5).

Figure 5
The ratio of AMH and InhB in the cohorts of community dwelling men.


This study shows that the hormonal output of Sertoli cells persists in the very old, but with characteristics that differ on average from younger men. The levels of both AMH and InhB were highly variable in the elderly men, with mean values approximating half those of younger men. This is consistent with histological studies of the testes showing age-related attrition of Sertoli cells [20], [21]. A small minority of men had minimum levels of both AMH and InhB, indicating a near complete cessation of their Sertoli cell output. In this respect, these men are similar to post-menopausal women, who lose AMH and InhB due to regression of their ovarian follicular cells [26], [27], [28].

There was an age-related increase in the inter-person variation in the levels of AMH and InhB, suggesting that the regulation of Sertoli cell output changes in some elderly men. A dysynchrony between LH and testosterone occurs in elderly men [29]. Consequently, alteration of the gonadal-pituitary axis may also be important for age-related changes in Sertoli cell hormones, as FSH regulates InhB [30] and as AMH is putatively under the control of GnRH [31]. LH and FSH exhibit a circhoral rhythm in men [32], whereas AMH has a half-life of greater than a day [33]. Hence, repeated hormonal measurements of individual will be needed to examine this hypothesis, rather than the cross-sectional approach used in this study.

The vascular cohort, which was free from cardiovascular disease, had higher levels of AMH and tended to have a higher AMH to InhB ratio. The most obvious difference between the cohorts is the proven absence of cardiovascular disease in the vascular cohort. The importance of this is currently unknown, although it is consistent with recently observations linking AMH to atherosclerosis in rhesus monkeys [34] and to the diameter of the abdominal aorta in health men [12].

As noted previously, the levels of InhB were lower in older men, with high statistical significance. This contrasts with a previous study by Mahmoud et al, who reported higher InhB levels in the elderly, with minimal age-related deterioration [22]. Mahmoud et al’s study excluded men being treated for diabetes mellitus, whereas the current study includes a more representative cross-section of elderly men. Low AMH in younger adults has also been associated with metabolic syndrome [35]. If Sertoli cell function is causally linked to insulin resistance, then changes in Sertoli cell output may contribute to age-related increase in the incidence of Type 2 diabetes mellitus and related complications. This points to the need for epidemiological studies examining the relationship between AMH levels and health status.

Secular changes have been observed in the androgen status of elderly men, with men born in earlier generations having higher levels of testosterone than more recent generations [36]. The current study is cross-sectional, and we therefore do not exclude the possibility that some of the observed age-related changes in Sertoli hormones also arise from intergenerational differences.

In summary, this study suggests that the plasma levels of Sertoli hormones decline with aging, but with high variability. There are associations between AMH, InhB and the ratio of AMH/InhB to the health status of elderly men. This identifies an area for future research, particularly into the role of Sertoli hormones in cardiovascular disease and frailty in elderly men.

Supporting Information

Figure S1

Distribution of AMH levels in men. A: the young subset of community dwelling men in Otago (n = 106, 19–67 years), B: the older subset in Otago (n = 99, 70–90 years). Both distributions were positively skewed (skewness 1.35 for young subset (p<0.001), 2.06 for older subset (p<0.001)).


Figure S2

Distribution of InhB in men. A: young subset of community dwelling men in Otago (n = 106, 19–67 years), B: older subset in Otago (n = 99, 70–90 years). The young subset cohort was normally distributed, but the older cohort was positively skewed (skewness 0.04 for young subset (p = 0.85), 0.11 for older subset (p = 0.64)).



The authors thank the participants of the two Dunedin cohorts. We also extend our appreciation to the Māori and non-Maori participants of the LiLAC Study NZ and RoopuKaitiaki o Nga Tikanga Māori and researchers involved in this study for agreement to share blood samples for analysis as part of this study. Mrs. Nicola Batchelor, Miss Marion Weimer, and Mrs Vicky Phillips are thanked for their expert technical laboratory assistance, Associate Professor Sheila Williams for her statistical advice and Karen Hayman for organization of laboratory and storage processes in LiLACS NZ. YHC is a recipient of the Frances Cotter PhD Scholarship (Dunedin School of Medicine, University of Otago).

Funding Statement

This study was funded by the following sources: Ministry of Business, Innovation and Employment, New Zealand; Health Research Council of New Zealand; Nga Pae o te Maramatanga, New Zealand; Oakley Mental Health Foundation, New Zealand; National Heart Foundation, New Zealand; and the Faculty of Medical and Health Sciences, University of Auckland, New Zealand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. MacLaughlin DT, Donahoe PK (2004) Sex determination and differentiation. New Eng J Med 350: 367–378 [PubMed]
2. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, et al. (1996) Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 81: 571–576 [PubMed]
3. Aksglaede L, Sorensen K, Boas M, Mouritsen A, Hagen CP, et al. (2010) Changes in Anti-Mullerian Hormone (AMH) throughout the life span: A population-based study of 1027 healthy males from birth (cord blood) to the age of 69 years. J Clin Endocrinol Metab 95: 5357–5364 [PubMed]
4. Halm S, Rocha A, Miura T, Prat F, Zanuy S (2007) Anti-Mullerian hormone (AMH/AMH) in the European sea bass: its gene structure, regulatory elements, and the expression of alternatively-spliced isoforms. Gene 388: 148–158 [PubMed]
5. Wang PY, Protheroe A, Clarkson AN, Imhoff F, Koishi K, et al. (2009) Müllerian Inhibiting Substance contributes to sex-linked biases in the brain and behavior. Proc Natl Acad Sci U S A 106: 7203–7208 [PubMed]
6. Wittmann W, McLennan IS (2011) The male bias in the number of Purkinje cells and the size of the murine cerebellum may require Mullerian inhibiting substance/anti-Mullerian hormone. J Neuroendocrinol 23: 831–838 [PubMed]
7. Morgan K, Meredith J, Kuo J-YA, Bilkey DK, McLennan IS (2011) The sex bias in novelty preference of preadolescent mouse pups may require testicular Müllerian inhibiting substance. Behav Brain Res 221: 304–306 [PubMed]
8. Catlin EA, Powell SM, Manganaro TF, Hudson PL, Ragin RC, et al. (1990) Sex-specific fetal lung development and mullerian inhibiting substance. Am Rev Respir Dis 141: 466–470 [PubMed]
9. Morgan K, Dennis NA, Ruffman T, Bilkey Dk, McLennan IS (2011) The stature of boys is inversely correlated to the levels of their Sertoli cell hormones: Do the testes restrain the maturation of boys? PLoS One 6: e20533. [PMC free article] [PubMed]
10. Pankhurst MW, McLennan IS (2012) Inhibin B and anti-Mullerian hormone/Mullerian-inhibiting substance may contribute to the male bias in autism. Transl Psychiatry 2: e148. [PMC free article] [PubMed]
11. Wang PY, Koishi K, McGeachie AB, Kimber M, Maclaughlin DT, et al. (2005) Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. Proc Natl Acad Sci USA 102: 16421–16425 [PubMed]
12. Dennis NA (2012) Is Anti-Mullerian hormone a hormone. Dunedin: University of Otago.
13. Ricci M, Mohapatra B, Urbiztondo A, Birusingh RJ, Morgado M, et al. (2010) Differential changes in TGF-beta/BMP signaling pathway in the right ventricular myocardium of newborns with hypoplastic left heart syndrome. J Card Fail 16: 628–634 [PubMed]
14. O'Connor AE, De Kretser DM (2004) Inhibins in normal male physiology. Semin Reprod Med 22: 177–185 [PubMed]
15. Nicks KM, Perrien DS, Akel NS, Suva LJ, Gaddy D (2009) Regulation of osteoblastogenesis and osteoclastogenesis by the other reproductive hormones, Activin and Inhibin. Mol Cell Endocrinol 310: 11–20 [PMC free article] [PubMed]
16. Andersson AM, Skakkebaek NE (2001) Serum inhibin B levels during male childhood and puberty. Mol Cell Endocrinol 180: 103–107 [PubMed]
17. Yan W, Burns KH, Matzuk MM (2003) Genetic engineering to study testicular tumorigenesis. APMIS 111: 174–181 [PubMed]
18. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700 [PubMed]
19. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87: 589–598 [PubMed]
20. Johnson L, Zane RS, Petty CS, Neaves WB (1984) Quantification of the human Sertoli cell population: its distribution, relation to germ cell numbers, and age-related decline. Biol Reprod 31: 785–795 [PubMed]
21. Johnson L, Petty CS, Neaves WB (1986) Age-related variation in seminiferous tubules in men. A stereologic evaluation. J Androl 7: 316–322 [PubMed]
22. Mahmoud AM, Goemaere S, De Bacquer D, Comhaire FH, Kaufman JM (2000) Serum inhibin B levels in community-dwelling elderly men. Clin Endocrinol (Oxf) 53: 141–147 [PubMed]
23. Hayman KJ, Kerse N, Dyall L, Kepa M, Teh R, et al. (2012) Life and living in advanced age: A cohort study in New Zealand -Te Puawaitanga o Nga Tapuwae Kia Ora Tonu, LiLACS NZ: Study protocol. BMC Geriatr 12: 33. [PMC free article] [PubMed]
24. Dyall L, Kepa M, Hayman K, Teh R, Moyes S, et al. (2013) Engagement and recruitment of Maori and non-Maori people of advanced age to LiLACS NZ. Aust NZ J Public Health 37: 124–131 [PubMed]
25. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, et al. (2009) Clinical uses of anti-Müllerian hormone assays: pitfalls and promises. Fertil Steril 91: 226–230 [PubMed]
26. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IAJ, de Vet A, et al. (2011) Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. J Clin Endocrinol Metab 96: 2532–2539 [PubMed]
27. Burger HG, Dudley EC, Hopper JL, Groome N, Guthrie JR, et al. (1999) Prospectively Measured Levels of Serum Follicle-Stimulating Hormone, Estradiol, and the Dimeric Inhibins during the Menopausal Transition in a Population-Based Cohort of Women. J Clin Endocrinol Metab 84: 4025–4030 [PubMed]
28. Chong YH, Farrand S, Campbell AJ, McLennan IS (2012) Anti-Müllerian Hormone level in older women - detection of granulosa cell tumor recurrence. Int J Gynecol Cancer In Press.. [PubMed]
29. Pincus SM, Mulligan T, Iranmanesh A, Gheorghiu S, Godschalk M, et al. (1996) Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males. Proc Natl Acad Sci U S A 93: 14100–14105 [PubMed]
30. Hedger MP, Winnall WR (2012) Regulation of activin and inhibin in the adult testis and the evidence for functional roles in spermatogenesis and immunoregulation. Mol Cell Endocrinol 359: 30–42 [PubMed]
31. Eldar-Geva T, Liberty G, Chertin B, Fridmans A, Farkas A, et al. (2010) Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. Eur J Endocrinol 162: 177–181 [PubMed]
32. Bergendahl M, Evans WS, Veldhuis JD (1996) Current concepts on ultradian rhythms of luteinizing hormone secretion in the human. Hum Reprod Update 2: 507–518 [PubMed]
33. Vigier B, Tran D, du Mesnil du Buisson F, Heyman Y, Josso N (1983) Use of monoclonal antibody techniques to study the ontogeny of bovine anti-Mullerian hormone. Journal of Reproduction & Fertility 69: 207–214 [PubMed]
34. Appt SE, Chen H, Clarkson TB, Kaplan JR (2012) Premenopausal antimullerian hormone concentration is associated with subsequent atherosclerosis. Menopause 19: 1353–1359 [PMC free article] [PubMed]
35. Robeva R, Tomova A, Kirilov G, Kumanov P (2012) Anti-Mullerian hormone and inhibin B levels reflect altered Sertoli cell function in men with metabolic syndrome. Andrologia 44 Suppl 1329–334 [PubMed]
36. Andersson A-M, Jensen TK, Juul A, Petersen JH, Jørgensen T, et al. (2007) Secular Decline in Male Testosterone and Sex Hormone Binding Globulin Serum Levels in Danish Population Surveys. J Clin Endocrinol Metab 92: 4696–4705 [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science